6BrCaQ is a promising anti-cancer agent derived from novobiocin, which has been shown to inhibit Hsp90. 6BrCaQ was loaded into nanometer-scaled phospholipid vesicles (liposomes) suitable for drug delivery to solid tumors. The effective incorporation of the drug within the phospholipid bilayer was investigated by differential scanning calorimetry. Liposomal 6BrCaQ showed good activity on PC-3 cell lines in vitro in terms of apoptosis induction and cell growth arrest in G2/M. Liposomes containing 6BrCaQ were also shown to slow down migration of PC-3 cells in presence of chemokine ligand 2 and to synergize with doxorubicin. Several Hsp90 targeting molecules like Geldanamycin induce accumulation of Hsp70, leading to cytoprotection and often correlated with poor prognosis. In this study, we did not report any Hsp70 induction after treatment with liposomal 6BrCaQ but a decrease in Hsp90 and CDK-4 protein expression, indicating an effect on the chaperon machinery. Liposomal encapsulation of 6BrCaQ reveals promising anti-cancer effects and a better understanding of its mechanism of action.
Formulation and in vitro efficacy of liposomes containing the hsp90 inhibitor 6BrCaQ in prostate cancer cells / F. Sauvage, S. Franzè, A. Bruneau, M. Alami, S. Denis, V. Nicolas, S. Lesieur, F.X. Legrand, G. Barratt, S. Messaoudi, J. Vergnaud Gauduchon. - In: INTERNATIONAL JOURNAL OF PHARMACEUTICS. - ISSN 0378-5173. - 499:1/2(2016 Feb 29), pp. 101-109. [10.1016/j.ijpharm.2015.12.053]
Formulation and in vitro efficacy of liposomes containing the hsp90 inhibitor 6BrCaQ in prostate cancer cells
S. Franzè;
2016
Abstract
6BrCaQ is a promising anti-cancer agent derived from novobiocin, which has been shown to inhibit Hsp90. 6BrCaQ was loaded into nanometer-scaled phospholipid vesicles (liposomes) suitable for drug delivery to solid tumors. The effective incorporation of the drug within the phospholipid bilayer was investigated by differential scanning calorimetry. Liposomal 6BrCaQ showed good activity on PC-3 cell lines in vitro in terms of apoptosis induction and cell growth arrest in G2/M. Liposomes containing 6BrCaQ were also shown to slow down migration of PC-3 cells in presence of chemokine ligand 2 and to synergize with doxorubicin. Several Hsp90 targeting molecules like Geldanamycin induce accumulation of Hsp70, leading to cytoprotection and often correlated with poor prognosis. In this study, we did not report any Hsp70 induction after treatment with liposomal 6BrCaQ but a decrease in Hsp90 and CDK-4 protein expression, indicating an effect on the chaperon machinery. Liposomal encapsulation of 6BrCaQ reveals promising anti-cancer effects and a better understanding of its mechanism of action.File | Dimensione | Formato | |
---|---|---|---|
1-s2.0-S0378517315304531-main.pdf
accesso riservato
Tipologia:
Publisher's version/PDF
Dimensione
1.43 MB
Formato
Adobe PDF
|
1.43 MB | Adobe PDF | Visualizza/Apri Richiedi una copia |
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.